Article: ProMetic and Halozyme Enter Into Long-Term Supply Agreement.

MONTREAL, QUEBEC, Nov 9, 2009 (Marketwire via COMTEX) -- ProMetic Life Sciences Inc. (TSX:PLI)("ProMetic") announced today that Halozyme Therapeutics, Inc. (Nasdaq:HALO)("Halozyme") and ProMetic have entered into a long-term supply agreement for a proprietary synthetic ligand affinity adsorbent manufactured by ProMetic's UK subsidiary, ProMetic BioSciences Ltd.

The agreement is for an initial five-year term with the opportunity for future extension. Other aspects of the agreement were not disclosed for reasons of client confidentiality. The synthetic ligand adsorbent provided under the supply agreement is used by Halozyme in the manufacture of its rHuPH20 ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!